Please note that masks are still required in all Blue Ridge Cancer Care offices regardless of vaccination status.
Learn more about this and other current Covid-19 policies.

Research Institute

Phase 3 Study of Navitoclax in Myelofibrosis

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Navitoclax in Combination with Ruxolitinib versus Ruxolitinib in Subjects with Myelofibrosis

Disease Types: Hematology

Available at: AlleghanyBlacksburgRoanokeSalemWytheville

For more information:

https://clinicaltrials.gov/ct2/show/NCT04472598?term=TRANSFORM-1&draw=2&rank=1